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Past research and case studies have shown that chemotherapy drugs appear to 
lessen the quality of friction ridge skin, thereby impacting cancer patients who are 
already experiencing a number of unpleasant side effects. Palmar-plantar 
erythrodysaesthesia, more commonly referred to as Hand-Foot Syndrome (HFS), is a 
common side effect of many chemotherapy agents and includes redness, swelling, and 
peeling of the skin of the hands and feet. This syndrome has been linked to a number of 
cases involving fingerprint loss, including a prior longitudinal study that evidenced 
degradation in response to capecitabine, a common chemotherapy agent. This research 
builds upon the prior study by assessing the effects of taxane class drugs and doxorubicin 
on the fingerprints. Impressions were collected from seven patients, five of which were 
prescribed taxane class drugs, and two of which were administered doxorubicin. Data 
was collected prior to treatment and at the three-month mark, which represents the 
halfway point of the general six-month administration cycle. Impressions were inputted 
into AFIX Tracker software to determine the number of minutiae points by way of the 
Smart-Extract feature. The data suggests no definitive decrease between taxane class 
drugs and the quality of the impressions. A singular patient who had been prescribed 
doxorubicin, however, experienced quality decrease, and may have been affiliated with 
HFS. No other significant HFS was discovered with any of the patients, which further 
certifies the link between HFS and ridge degradation.  
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Exclusivity of Friction Ridge Skin 
Fingerprint impressions are unique to each individual, allowing for an efficient 
mode of identification. In a medical context, the degradation of these impressions has the 
capacity to negatively impact patient quality of life. A reduced impression quality would 
also lessen the efficiency of this method of identification, which may create significant 
issues for patients who must provide their fingerprints for business or traveling purposes. 
Past research suggests a correlation between chemotherapy drugs and a reduced quality 
of friction ridge skin. By determining degradation factors, medical professionals may be 
alerted to needed adjustment of treatment plans or, in the very least, may be provided 
definitive side effect information for patient notification.  
Prior Research Initiatives 
Various research studies have associated capecitabine, a relatively common 
chemotherapy drug, to ridge degradation, and in extreme cases, lack of ridge detail. The 
majority of articles were written in response to individuals who were discovered to have 
no ridge detail when asked to provide identification for traveling purposes.1, 2 After 
subsequent investigation, all reported cases were chemotherapy patients who had been 
prescribed capecitabine. Based on this data, a longitudinal study was conducted to isolate 
the effects of capecitabine on a chemotherapy patient throughout the treatment process. 
The results showed a direct relationship between capecitabine and ridge degradation, with 
ridge detail returning to relatively normal levels approximately 65 days following 
cessation of treatment.3  
 2 
Distinctiveness of Study and Brief Methodology 
This study will build upon a prior study through an assessment of the effects of 
multiple chemotherapy drugs on impression quality. The study analyzed levels of 
degradation, or lack thereof, in relation to drug class and treatment cycle. It also 
correlated reduced ridge visibility with age, dosage, frequency of treatment, history of 
treatment, and physical activities, all of which may promote research implications. Data 
was collected from chemotherapy patients who have been prescribed the aforementioned 















Chapter 2—Literature Review 
Skin Layers   
Throughout the litigation process, evidence that is dependable, such as the 
exclusivity of a fingerprint, augments the position on which a case is founded. 
Fingerprint impressions, more commonly referenced in forensic science as friction ridge 
skin, are unique to every individual. Their uniqueness is based upon fundamental 
biological principles of the skin. Friction ridge skin is grounded in the dermis, the second 
of three skin layers.4 The outer layer of skin, the epidermis, functions primarily as a 
barrier between lower levels of tissue and foreign substances in the surrounding 
atmosphere. Though the epidermis is made up of a multitude of cell types, all of which 
serve a specialized function, keratinocytes are the primary type of cell in the epidermis, 
constituting 90-95 percent of the layer.5 
Figure 1.1 illustrates the five layers 
of keratinocytes characteristic of the 
epidermis of the hand. Each layer is 
distinct based upon cellular structure 
and rigidity. As cells in the basal 
layer undergo mitosis and are 
propelled upward, the cells gradually 
harden.4 This process, known as keratinization, involves the production of the protein 
keratin, a fortifying cellular agent required to manage the daily strain sustained by the 
epidermis. Fully differentiated layers are sloughed off at the surface, creating a 
continuous balance of production, keratinization, and depletion.4 
Figure 1 Keratinocyte Layers 4 
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The dermis is the second skin layer, serving as a structural foundation for the 
epidermis and a regulation site for temperature and sensory reaction.4 Eccrine sweat 
glands, which primarily regulate body temperature, originate in the dermis or 
hypodermis, dependent on their length, and extend to the surface of friction ridge skin.4 
Also rooted in the dermis are subjacent projections of tissue, that correspond to the peaks 
and valleys of a fingerprint pattern. Primary ridges support the “peaks” of a fingerprint, 
while secondary skin ridges support the “valleys” of a given pattern.  
Beneath the dermis lies the hypodermis, which is made up of flexible, fatty tissue. 
The hypodermis provides for skin contouring and is composed of adipose tissue that 
stores lipids for energy production.5        
Formation of Friction Ridge Patterns and Minutiae 
The singularity of friction ridge skin is the 
result of natural biological development. 
During gestation, friction ridge skin is 
formed between 10.5 and 16 weeks.4 The 
fundamental concepts of cell 
proliferation and volar pad development 
determine the construction of unique 
friction ridge skin.4 Volar pads form as a 
result of inflammation of the tissue beneath the epidermis. This swelling of tissue begins 
at the thumb at approximately 7 weeks, as depicted in Figure 1.26, and slowly progresses 
to each adjacent finger.4 After eleven weeks, the volar pads begin to change shape as 
cells present in surrounding tissue rapidly divide and combine with volar pad tissue. This 
Figure 2 Volar Pad Development 6 
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process yields a recognizable delineation of the hand and fingers at approximately 16 
weeks.7  
The foremost theory of ridge formation holds that basal cells in the epidermis 
rapidly divide at approximately 10.5 weeks.8 Cell groupings join together and develop 
into randomized patterns.4 Figure 1.36 illustrates this theory. As each finger increases in 
size, the ridges that have developed are distanced, and additional ridges form to fill in the 
space.11  
The cell’s ability to fill in space in order 
to maintain consistency corresponds to 
minutiae formation. Minutiae, or distinct 
locales present on friction ridge skin, create 
distinction between fingerprint impressions. 
Essentially, minutiae are variations of ridge 
structure and fall under two distinct 
categories: ridge endings and bifurcations.12  
 In addition to the minutiae present on 
friction ridge skin, each impression can be 
divided into one of three classes of ridge patterns: loops, whorls, and arches, all of which 
are dependent on volar pad size and regression behavior.4 In summary, the height of the 
volar pad and the shape it takes as surrounding areas of tissue begin to slowly grow may 
affect the size and orientation of the pattern.4, 13-15 Loops are the most common type of 
pattern, occurring in approximately 60 percent of the population. They originate from one 
side of the print, curve around, and continue toward the side from whence it originated.16, 
Figure 3 Formation of Friction 
Ridge Skin 6 
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17 Whorls are circular in shape, and are the second most common type of pattern, 
occurring in approximately 35 percent of the population.17 The last pattern type, arches, 
are the least common pattern, with a 5 percent occurrence in the population. Arches begin 
on one side of the print and exit on the opposite side.16,17 Loops, whorls, and arches can 
be classified according to two points, known as core and delta points. Core points are the 
approximate center of a pattern, or the location at which central ridges are at their 
steepest. Each pattern has a core. A delta can be defined as the point at which ridges 
diverge. Loop patterns have one delta, while whorl patterns have two deltas.16 
Case Report Studies Depicting Hand-Foot Syndrome 
This research study measured the degradation, or lack thereof, of ridge detail in 
conjunction with drug class and treatment cycle. Additional medical history that may 
account for degradation, including age, dosage, frequency of treatment, past history, and 
physical activities will also be observed. As previously denoted, each individual has 
unique friction ridge skin. In a medical context, the degradation or loss of friction ridge 
skin adversely affects patients whose quality of life has already been diminished. 
According to Al-Ahwal (2012), clinicians should place greater focus on the potential loss 
of ridge detail, which could add significantly more stress to cancer patients whose lives 
have already been severely altered.2 The author describes the case report of a 53-year old 
male patient diagnosed with stage IV adenocarcinoma metastasized to the liver, lungs, 
and rectum.2 As part of a palliative care regimen, the patient was administered 
capecitabine, an anti-metabolic drug that prevents the growth of cancer cells by inhibiting 
DNA and RNA production.18 After fifteen days of treatment, the patient presented with 
grade 1 Hand-Foot Syndrome (HFS) following the second and third cycles of 
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chemotherapy. Following the fifth and sixth chemotherapy administration cycles, the 
patient exhibited grade 3 HFS and fingerprint loss.2 
Hand-Foot Syndrome, scientifically referred to as palmar-plantar 
erythrodysesthesia (PPE), is a common adverse response to chemotherapy drug 
administration. HFS manifests as erythema (reddening) and dysesthesia (numbing 
sensation) localized to the palms of the hands and the soles of the feet. Patients with 
severe cases of HFS present with swelling and blistering of the skin accompanied by 
desquamation (the shedding of skin layers).9 The National Cancer Institute classifies HFS 
into three grades that correspond to severity. Grade 1 HFS is characterized as erythema 
with no pain or discomfort; Grade 2 HFS presents as skin peeling, blistering, and 
bleeding accompanied by edema (fluid build-up); Grade 3 HFS most significantly affects 
routine activities and is characterized as ulceration in addition to previous grade 
symptoms.10 
A separate report, published by Wong, Choo, and Tan, presents the case of a 62-
year old male patient diagnosed with metastatic nasopharyngeal carcinoma. Following 
treatment, doctors placed the patient on a capecitabine regimen in July 2005 to sustain 
remission status.1 After follow-up appointment, the patient was prescribed a continuation 
of the dosage. In December 2008, three years following the initial capecitabine treatment, 
airport officials were unable to locate ridge detail, and the patient was detained for 
several hours at airport customs and impeded from entering the country.1 The authors’ 
note that many patients who undergo long-term capecitabine administration may 
experience loss of prints and should be notified to avoid inconvenience.1 
 
 8 
Capecitabine and Ridge Degradation 
Capecitabine, or Xeloda, is an anti-metabolic drug that is orally administered to 
catalyze the effects of Fluorouracil, a substance that prevents cancerous growth by 
inhibiting DNA and RNA production.19 Without DNA and RNA, cells are unable to 
properly function and reproduce. Though the prevalence of HFS is markedly higher with 
capecitabine administration, there are additional drugs associated with HFS. The 
following are examples of drugs that have been cited with HFS symptoms: Cytaribine, 
Floxuridine, Fluorouracil, Idarubicin, Liposomal doxorubicin, Doxorubicin, Sunitinib, 
Sorafenib, Pazopanib, and Vemurafenib.3 
The developmental process of capecitabine-induced HFS is currently being 
studied.3, 20, 22-24 Current hypotheses on the subject speculate that both cancerous and 
epidermal cells are susceptible to the toxic effects of capecitabine.3 Other hypotheses 
suggest changes in the skin occur when small amounts of chemotherapy seep out of the 
blood vessels in the extremities and are introduced to surrounding tissue.3 Still other 
hypotheses suggest that chemotherapy drugs, like excess water and salts, are emitted 
from the body as waste products by way of pores that are linked to eccrine sweat glands. 
3, 25  
 Several of these hypotheses appear to be plausible based on the conversion 
process of Fluorouracil into an effective cancer targeting substance.3, 5 The introduction 
of capecitabine into the system causes numerous reactions to take place, leading to the 
eventual conversion of Fluorouracil to 5-FU.3 Specifically, the enzyme thymidine 
phosphorylase, or TP, aggregates at cancerous sites in large quantities and converts 
Fluorouracil to 5-FU, thereby limiting its toxic effects to cancerous tissue.19 Studies have 
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shown that TP is more prevalent in friction ridge skin than other areas of the body, 
suggesting that the increased proliferation of keratinocytes in the epidermis draws 5-FU 
to these areas in much the same way that the substance is drawn to areas with high 
proliferation of cancerous cells.3, 19 
Longitudinal Study of Ridge Degradation 
 A longitudinal study conducted by Schenck documented the effects of 
capecitabine on a single patient from initial administration to final treatment.3 The study 
evidenced diminished friction ridge skin in relation to capecitabine administration. The 
study also attested to the permanency of friction ridge skin; though ridges were exposed 
to toxic medication, detail was restored to close to initial condition approximately 65 
days after treatment, with no change in pattern or minutiae arrangement.3 These results 
are depicted in Figure 1.4. Section “A” displays quality of ridge detail at the beginning of 
treatment, “B” showcases the quality throughout duration of treatment, “C” is indicative 
of quality at cessation of treatment, and “D” signals the return of normal ridge detail. The 
study evidences a direct result between capecitabine and a decline in impression quality.3 
These findings verify previous literature that estimates keratinocyte maturation to be 
between 30 to 40 days.6 The decline of observed quality correlates to a significant 
disruption in basal layer proliferation, suggesting that these rapid areas of growth were 
susceptible to 5-FU in much the same way as cancerous growth and required 
approximately 30 to 40 days for friction ridge detail to be apparent on the upper 
epidermal layer.3
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 The author challenges researchers to build upon this research initiative by 
documenting the results of varying capecitabine dosages as well as the effects additional 
chemotherapy drugs on friction ridge detail.3 The present study addressed one portion of 
this challenge, calling for observation of the effects of Taxane class drugs and 
Doxorubicin on friction ridge skin. 
Taxane Class Drugs and Anti-Microtubule Mechanism 
  Taxane class drugs are anti-microtubule reagents whose principle mechanism is 
the stabilization of guanosine diphosphate (GDP)-bound tubulin in the microtubule.26 The 
protein tubulin polyermizes in vitro to form microtubules, or fibrous cellular projections 
that support cellular activity, including spindle fiber formation during mitosis.27 Many 
anti-microtubule reagents stop cellular growth by preventing polymerization; however, 
taxane class drugs operate with a reverse mechanism. Taxane class drugs inhibit mitosis 
by binding to tubulin and preventing it from depolymerizing.30 In summary, once spindle 
fibers are formed, taxane class drugs prevent the fibers from decreasing in size, and 
therefore, prohibit chromosomes from separating, a crucial step in mitosis.  
Figure 4 Longitudinal Study Results: Ridge Quality in Relation to Cycle of Treatment 3 
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Taxane drugs, derived from the plant genus Taxus, include Paclitaxel (Taxol) and 
Docetaxel (Taxotere).26 These drugs are administered by injection, with common side 
effects including swelling, rash, and painful separation of the nail from the nail bed.26 
HFS is a reported side effect of taxane class drugs, with paclitaxel at a ten percent 
occurrence and docetaxel at a five percent occurrence.26, 28-29 Taxane-induced HFS is 
reported more frequently with relatively large doses that are administered in quick 
succession.26 
Several case reports detail both paclitaxel and docetaxel-induced HFS.30,31 The 
first case report details a 72-year old patient diagnosed with stage T1 breast cancer and 
prescribed a weekly injection of paclitaxel over a span of twelve weeks.30 Following the 
sixth dosage of paclitaxel, the patient was diagnosed with grade 3 HFS, characterized by 
redness, desquamation, and dysesthesia. The patient was instructed to wear long articles 
of clothing and generously apply sun block to the affected areas, which yielded 
improvement and continuation of the 12-week treatment.30 The second and final case 
report details a 52-year old patient diagnosed with metastatic breast carcinoma. The 
patient was administered two weekly cycles of docetaxel, after which, the patient 
presented with grade 3 HFS characterized by severe redness and swelling.31 Although the 
patient was prescribed a dosage that has not presented HFS in the past, professionals are 
certain that the patient’s metastatic condition altered metabolism of the drug, causing 
symptoms at a lower dosage.31 Despite the incidence of HFS, no reports exist describing 




Liposomal Doxorubicin (Doxil) and Anthracycline Mechanism 
Liposomal Doxorubicin, or Doxil, is an antitumor anthracycline, a drug class 
derived from the Streptomyces fungus species. The drug is composed of doxorubicin 
encased in a liposome, or lipid, to allow for direct contact with cancerous tumor growths 
upon injection without detection by the immune system.32 Though the exact targeting 
mechanism of the drug is currently unclear, scientists Denard, Lee, and Ye of the 
University of Texas Southwestern (UTSW) Medical Center have contributed to research 
on this subject. Their research evidences that a viral infection prompts the detachment of 
a protein, CREB3L1, and its corresponding amine group from the cellular membrane. 
The protein and amine travel to the nucleus, where genetic code is transcribed, including 
code that inhibits cellular proliferation.33, 34 The UTSW group has found that doxorubicin 
prompts the formation of lipid molecules known as ceramides, which aid in detaching 
CREB3L1 from the membrane.33, 35 Though the exact mechanism of cellular breakdown 
by doxorubicin is unclear, these findings provide information that can be built upon 
through further analysis.  
There are several noted changes in the skin as a result of doxorubicin 
administration; HFS is a common side effect of doxorubicin, occurring five to six weeks 
following treatment in approximately 30 percent of cases. In approximately 10 to 29 
percent of all patients, the drug darkens and discolors the nail bed. 32 
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Chapter 3—Methodology  
Overview of Academic Partnership and Objectives 
Collection of fingerprints took place in the Chemotherapy Infusion Suite of the 
University of South Alabama Mitchell Cancer Institute (USAMCI), located at 1660 
Springhill Avenue in Mobile, Alabama. Michael A. Finan, M.D., Director of the Mitchell 
Cancer Institute, and Dr. Rodney P. Rocconi, M.D., Associate Director for Clinical 
Research, agreed to a research partnership with the University of Southern Mississippi’s 
School of Criminal Justice following in tandem approval of the University of Southern 
Mississippi and South Alabama Internal Review Boards. Dr. Jenna Wildman, a resident 
enrolled in the University of South Alabama College of Medicine, and Lynley Walsh, a 
nurse at the Mitchell Cancer Institute, assisted with data collection. 
Primary objectives of study protocol were to conduct a study of the effects of 
taxane class drugs and liposomal doxorubicin on friction ridge skin. Principal aims 
included sharing data with USAMCI in order to provide essential information for patient 
notification. Secondary objectives included analysis of treatment plans and prior medical 
history in conjunction with generated quality scores to determine statistical trends.  
Study Population  
Partnership with USAMCI was utilized to identify seven patients who had been 
prescribed taxane class drugs or liposomal doxorubicin. Specifically, five patients were 
enrolled in the study who were administered taxane class drugs and two participants who 
were administered doxorubicin. Though the original proposed study aimed for a larger 
study population, the population was limited in order to be conducive to time constraints. 
Chemotherapy combinations containing the studied drugs were admitted to the study and 
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additional drugs present were noted. After all patients were admitted to the study, ridge 
detail impressions were collected for further analysis and interpretation.  
Data was collected upon diagnosis and at the halfway point of treatment (3 
months). This research initiative was classified as a pilot study that the researcher intends 
to build upon in the future. The researcher aims to gather impressions throughout the 
entire chemotherapy treatment period that typically lasts 6 months. Impressions were 
gathered prior to the first chemotherapy cycle, at the halfway point (3 months), and will 
be gathered at completion of chemotherapy (6 months). Additionally, a post-
chemotherapy impression will be obtained to assess resolution of ridge detail at 90 days 
+/- 14 days. These impressions will only be gathered in the event that the data evidences 
definitive degradation. 
Exclusion criteria included individuals who were not prescribed taxane class 
drugs or doxorubicin. No individual who met inclusion criteria was excluded from the 
study due to race, ethnicity, socioeconomic status, or gender. Patients were provided with 
a consent form and were informed of their rights to refuse participation. Prior to 
collection and at the discretion of the guidelines for Human Subjects Research and the 
researcher, all probable participants demonstrated an understanding of the extent of the 
study, including any and all potential benefits and harm. All consent forms were signed 
prior to data collection. 
Research Design 
 Friction ridge skin impressions were collected utilizing the powder/label 
technique.36 A relatively common postmortem lift technique, this method showcases 
clearer ridge detail in comparison to the traditional ink method, as indicated in Figure 
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1.5.36 The powder/label technique 
necessitates the direct application of 
black fingerprint powder to the skin by 
a fingerprint brush. Following the light 
coating of powder onto the skin, the 
adhesive side of a white mailing label 
was slowly applied to one side of the 
finger to reduce doubling the impression and was then flattened onto the remainder of the 
finger.36 The label was applied to the backside of a clear acetate ten-print card, 
correspondent to the appropriate finger from which the impression was collected. Residue 
was cleaned from the skin using hand wipes.36  
During the collection period, the researcher and all collaborators maintained a 
central logbook in which patient name corresponded to a unique study identification 
number. The logbook was stored at USAMCI in a locked cabinet with access provided 
only by the clinical trial staff of the USAMCI.  All investigators and clinical trial staff 
had completed and maintained HIPPA training and certification. Dr. Wildman and 
Lynley Walsh assisted with clinical data collection and was informed and educated of the 
identification system, which remained prevalent throughout the study. When patient 
information was needed, study identification numbers were provided via email to these 
individuals, who provided the corresponding materials.  
All clinical data was de-identified and maintained on a password-protected 
spreadsheet on the researcher’s computer. All collected impressions were labeled with the 
Figure 5 Comparison of Powder and Ink Lift 
Methods 36 
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study number and transported by the researcher back to the University of Southern 
Mississippi School of Criminal Justice Fingerprint Laboratory for analysis.  
Data Analysis and Interpretation 
Collected data was analyzed using a scoring system existent in a database known 
as AFIX Tracker.37 The software has the capability to allow for both comparison of a 
collected print to a database and individual analysis of a single impression. The latter 
capability was utilized and is referred to as the “Smart-Extract” feature, which assesses 
impression quality by automatically identifying the number of minutiae points on a 
particular print. This number is referred to as a quality score. Each individual set of ten 
prints was scanned into the software and the scores of each finger recorded five separate 
times in order to gather a more holistic data set. 
Statistical analyses were performed to evaluate impression quality, impression 
scores correlated to chemotherapy agents received and associated clinical factors, as well 
as chemotherapy administration details such as dosage, length of chemotherapy duration, 
and delays or reductions in chemotherapy. Additional variables include age of the patient, 
prior history, and physical activities.  
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Chapter 4—Results  
To begin the study, 200 sets of fingerprint impressions from the AFIX Tracker 
Database were selected at random and an average score for each finger was generated. 
This was done in order to provide readers with a general understanding of the average 
number of minutiae per finger with respect to normal quality and surface area. It should 
be noted that the first scores refer to the right hand thumb, followed by the right index 
finger, and so forth. The sixth score corresponds to the left hand thumb, followed by the 
left index finger, and so forth. The results are shown in the Table 1.1 below.  
 Baseline Averages from AFIX 
Tracker Database 
Avg. 1 79.495 
Avg. 2 59.525 
Avg. 3 60.955 
Avg. 4 50.270 
Avg. 5 35.205 
Avg. 6 81.950 
Avg. 7 55.675 
Avg. 8 58.845 
Avg. 9 47.445 
Avg. 10 34.705 
Table 1 Baseline Averages from AFIX Tracker Database 
After reviewing the taxane class drug data that corresponds to baseline and three-
month data, no definitive decrease in ridge quality was indicated. Although several of the 
scores obtained from AFIX Tracker decreased, the researcher noted increases in ridge 
quality as well, which is a testament to the surface area captured during collection and not 
that of chemotherapy. Additional variables that may have affected scores included the 
amount of powder applied, which causes slightly darker and lighter sections of an 
individual print that make reading by a scanner difficult. Regardless of the variables 
associated with decrease, it can be said that chemotherapy was not a variable to be 
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accounted for. If all of the taxane class drug impressions collected at three months had 
decreased, one could conclude that chemotherapy was a factor, but based on increases at 
three months, the methodology itself must be cited as cause for both increase and 
decrease. After examining the impressions directly, the researcher could find no marked 
decrease in ridge visibility or marked increase in lines and creasing. 
In contrast, one of the patients prescribed doxorubicin experienced significant 
ridge degradation in each impression. The AFIX Tracker scores associated with this 
participant are listed in Table 2 below. It should be noted that the first score corresponds 
to the right hand thumb, followed by the right index finger, and so forth. The sixth score 
from the top corresponds to the left hand thumb, followed by the left index finger, and so 
forth. 











Table 2 Comparisons of Baseline and Three-Month Scores of Doxorubicin Patient 
The researcher noticed significant decrease in ridge visibility in the majority of the 
impressions as a result of increased creasing that obstructs ridges from view. After 
meeting with the patient and a relative to collect data at the three-month mark, a comment 
was made regarding the patient’s issue with HFS. Though the symptom was not 
documented in the patient’s chart, a nurse verified that medical personnel rarely ask 
patients questions regarding HFS.  
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 The scores associated with the final doxorubicin participant were similar to those 
of the taxane class. There were both decreases and increases, which must be attributed to 
surface area and technique, and not to chemotherapy. However, the researcher noted 
slight decrease in ridge visibility, though AFIX was able to output increased scores.  
Study participants were between 27 and 84 years of age and were administered 
chemotherapy concoctions including paclitaxel and avastin, gemcitabine and docetaxel, 
paclitaxel and carboplatin, doxil and avastin, and simply, doxil. It should be noted that 
the patient following the gemcitabine and docetaxel regimen was prescribed a new set of 
chemotherapy drugs that are not being researched in this study, and therefore, the 
participant has been excluded from it.  
For those administered taxane class drugs, dosages ranged from 144 mg weekly to 
upward of 270 mg every three to four weeks. Patients prescribed doxil were administered 
approximately 60 mg of the drug every month. Several patients had prior history with 
these concoctions, while some patients have had reductions in dosage and changes in 
medication. To briefly cite the research survey distributed among participants, there were 
variations in physical activities and hobbies, including gardening and carpentry. Despite 
the numerous differences in concoctions, dosage, medical history, and physical activities, 
there was no definitive decrease in ridge detail for a majority of the study population. 
Furthermore, past research indicates that HFS has presented in taxane class drugs 
following the sixth weekly dosage of paclitaxel. Research on doxorubicin claims that 
HFS is evidenced five to six weeks following treatment in approximately thirty percent of 
cases. There was no evidence of the severe swelling, peeling, or blistering indicative of 
HFS in any of the patients. Though no severities were noted, based on the interaction 
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with the doxorubicin patient who experienced degradation, HFS may very well have 
presented at a lower grade. 
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Chapter 5—Conclusion  
Discussion of HFS Theories 
It is quite clear based on prior research initiatives that all of the chemotherapy 
drugs in question affect the human body in a way that is synonymous to cause HFS, 
though the exact mechanism in which chemotherapy causes this syndrome is unknown. 
The lack of both visible signs of HFS and corresponding fingerprint degradation does not 
disprove that these two variables may be related.  
There are a variety of theories that attempt to account for the mechanism of HFS. 
There are also a number of ways in which chemotherapy targets cancerous growth. In 
each mechanism, however, HFS has been cited in many cases. Dosage spacing of taxane 
class drugs ranged from every week to every three to four weeks. After assessing the case 
studies that evidenced HFS with respect to paclitaxel and docetaxel30-31, the researcher 
found that patients diagnosed with HFS received smaller dosages of taxane class drugs 
compared to study participants. Factors that may have influenced the presence of HFS 
include the metabolism of the drug in relation to premedications and the rate at which the 
drugs are administered.  
In the case of doxorubicin, the research indicates that HFS occurs in thirty percent 
of cases. In the research participants, dosages were administered every four weeks. Both 
doxorubicin participants were administered similar dosages every four weeks, though the 
patient who exhibited degradation was only administered doxil, as opposed to additional 
chemotherapy concoctions. Similar inferences from taxane class drug actions may be 
applied here as well; perhaps the drug brought about a decrease in ridge quality as a result 
of an interaction distinct from the other doxorubicin patient. 
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Study Limitations and Future Challenges 
Due to time constraints pertaining to the study, there were only two individuals 
enrolled who were prescribed doxorubicin. Enrolling additional patients on this drug 
would have made for a more conclusive study, and therefore, more comprehensive data 
in regards to percentages of disruption found in ridge detail.  
An additional verification for contemplation includes the methodology itself, 
specifically, the powder and label technique. Though research has shown that this 
technique is sublime in comparison to the traditional ink technique, Figure 1.5 showcases 
a larger surface area associated with the traditional technique, which may result in a 
surface area consistency.  
Perhaps most significantly, in order to prove or disprove theories that correlate 
HFS to fingerprint loss, future researchers should consider collecting fingerprint 
impressions at all grades of this syndrome to observe the presence or absence of ridge 
detail. Additional variables to include in relation to HFS are the premedications 
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